Triple-negative breast cancer and basal-like subtype : Pathology and targeted therapy
| Autor: | Tomoko Kobayashi, Satoshi Sumida, Yuko Miyakami, Hisanori Uehara, Yasuyo Saijo, Takumi Kakimoto, Yoshimi Bando |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
business.industry
intrinsic subtype medicine.medical_treatment Gene Expression Profiling Estrogen receptor Triple Negative Breast Neoplasms General Medicine Disease medicine.disease targeted therapy Phenotype General Biochemistry Genetics and Molecular Biology Targeted therapy Gene expression profiling basal-like subtype Breast cancer Receptors Estrogen medicine Cancer research triple-negative breast cancer Humans Personalized medicine business Triple-negative breast cancer |
| Zdroj: | The Journal of Medical Investigation. 68(3-4):213-219 |
| ISSN: | 1349-6867 |
| Popis: | Triple-negative breast cancer (TNBC) is a heterogenous disease. For personalized medicine, it is essential to identify and classify tumor subtypes to develop effective therapeutic strategies. Although gene expression profiling has identified several TNBC subtypes, classification of these tumors remains complex. Most TNBCs exhibit an aggressive phenotype, but some rare types have a favorable clinical course. In this review, we summarize the classification and characteristics related to the various TNBC subtypes, including the rare types. Therapeutic methods that are suitable for each subtype are also discussed. Of the intrinsic breast cancer subtypes identified by gene expression analysis, the basal-like subtype specifically displayed decreased expression of an estrogen receptor (ER) and human epidermal growth factor receptor 2 (HER2) cluster. We also present results that characterize the TNBC and basal-like phenotypes. TNBC may be categorized into four major classes : basal-like, immune-enriched, mesenchymal, and luminal androgen receptor. Therapeutic strategies for each subtype have been proposed along with newly approved targeted therapies for TNBC, such as immune checkpoint inhibitors. Understanding the classification of TNBC based on gene expression profiling in association with clinicopathological factors will facilitate accurate pathological diagnosis and effective treatment selection. J. Med. Invest. 68 : 213-219, August, 2021. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|